Background:
- Genomic scars assay measured by SNP (single nucleotide polymorphisms)-based tests are increasingly used clinically to identify patients more likely to benefit from PARP inhibitors (PARPi) in ovarian cancer.
- We aim to leverage the extensive SNP coverage built into a WES platform to accurately measure genomic loss of heterozygosity (LOH) and homologous recombination deficiency (HRD).
- We assessed the validity of WES compared to the whole genome sequencing (WGS) in identifying LOH.
- HRD was correlated with clinical outcome in PARPi-treated ovarian cancer patients.